Beacon Bioscience Unveils a New Name and New OfficesDoylestown, PA, March 12, 2007 Beacon Bioscience, Inc, a division of ICON plc (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced today that the company will change its name to ICON Medical Imaging, effective April 2, 2007.
A division of ICON plc since 2004, Beacon Bioscience is a leading provider of medical imaging services for clinical trials and has conducted over 250 Phase I- IV clinical trials across all key therapeutic areas. Following the name change the company will continue to focus on medical imaging services with the same corporate structure, management team and operational processes.
Beacon Bioscience CEO, Ted Gastineau, an industry-recognized expert in the application of medical imaging in clinical trials commented, “Our new name emphasizes the significance of our position within ICON. Medical imaging is an increasingly important factor in the successful conduct of many clinical studies. Across the spectrum of trial management services ICON offers, medical imaging has an important place, reflected by the fact that ICON Medical Imaging is one of ICON’s core divisions.”
Gastineau added, “As we make this change there will be complete continuity in both the work-flow and the experienced professionals who manage client studies. Our new name reflects the resources available to us through being part of the broader ICON group and reflects our ongoing commitment to development of innovative imaging services for clients.”
As part of the re-branding, the company will adopt a new “look and feel” consistent with ICON’s corporate branding. In conjunction with the name change, also on April 2, the imaging solutions provider will begin operating from a newly constructed headquarters, located in Warrington PA, 5 miles from its current location.
About Beacon Bioscience
Located in Doylestown, PA, Beacon Bioscience, Inc. is the leading provider of Medical Imaging core lab services to pharmaceutical, biotech and life science clients globally. The Company’s extensive experience and expert guidance allow clients to maximize the use of their medical imaging data, augmenting their current research and development capabilities. The team at Beacon Bioscience has managed over 250 imaging trials in cancer, cardiovascular, CNS, medical devices and imaging agents. Further information is available at www.beaconbioscience.com.
About ICON
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has over 4,300 employees, operating from 50 locations in 30 countries. Further information is available at www.iconclinical.com.
Contacts:
Betsy Robson
Beacon Bioscience, Inc.
Tel: +1 215 489 2626
Email: brobson@beaconbioscience.com
Back to press releases
A division of ICON plc since 2004, Beacon Bioscience is a leading provider of medical imaging services for clinical trials and has conducted over 250 Phase I- IV clinical trials across all key therapeutic areas. Following the name change the company will continue to focus on medical imaging services with the same corporate structure, management team and operational processes.
Beacon Bioscience CEO, Ted Gastineau, an industry-recognized expert in the application of medical imaging in clinical trials commented, “Our new name emphasizes the significance of our position within ICON. Medical imaging is an increasingly important factor in the successful conduct of many clinical studies. Across the spectrum of trial management services ICON offers, medical imaging has an important place, reflected by the fact that ICON Medical Imaging is one of ICON’s core divisions.”
Gastineau added, “As we make this change there will be complete continuity in both the work-flow and the experienced professionals who manage client studies. Our new name reflects the resources available to us through being part of the broader ICON group and reflects our ongoing commitment to development of innovative imaging services for clients.”
As part of the re-branding, the company will adopt a new “look and feel” consistent with ICON’s corporate branding. In conjunction with the name change, also on April 2, the imaging solutions provider will begin operating from a newly constructed headquarters, located in Warrington PA, 5 miles from its current location.
About Beacon Bioscience
Located in Doylestown, PA, Beacon Bioscience, Inc. is the leading provider of Medical Imaging core lab services to pharmaceutical, biotech and life science clients globally. The Company’s extensive experience and expert guidance allow clients to maximize the use of their medical imaging data, augmenting their current research and development capabilities. The team at Beacon Bioscience has managed over 250 imaging trials in cancer, cardiovascular, CNS, medical devices and imaging agents. Further information is available at www.beaconbioscience.com.
About ICON
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has over 4,300 employees, operating from 50 locations in 30 countries. Further information is available at www.iconclinical.com.
Contacts:
Betsy Robson
Beacon Bioscience, Inc.
Tel: +1 215 489 2626
Email: brobson@beaconbioscience.com